Morgan Stanley lifts Evofem Biosciences Inc. [EVFM] price estimate. Who else is bullish?

Related

Evofem Biosciences Inc. [NASDAQ: EVFM] gained 0.73% on the last trading session, reaching $0.72 price per share at the time. The company report on October 20, 2021 that “House Rules” Delivers Strong Initial Results and Drives Phexxi Growth.

– 71% increase in monthly ex-factory sales -.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


– 56% increase in the number of women starting Phexxi -.

Evofem Biosciences Inc. represents 125.17 million in outstanding shares, while the company has a total market value of $114.93 million with the latest information. EVFM stock price has been found in the range of $0.701 to $0.735.

If compared to the average trading volume of 3.57M shares, EVFM reached a trading volume of 2371909 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Evofem Biosciences Inc. [EVFM]:

Morgan Stanley have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on October 02, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $3, while Morgan Stanley analysts kept a Equal-Weight rating on EVFM stock.

The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.04, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 33.80. The Price to Book ratio for the last quarter was 10.22.

Trading performance analysis for EVFM stock

Evofem Biosciences Inc. [EVFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.59. With this latest performance, EVFM shares dropped by -6.10% in over the last four-week period, additionally sinking by -52.92% over the last 6 months – not to mention a drop of -72.89% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 42.55, with the RSI for the last a single of trading hit 41.95, and the three-weeks RSI is set at 43.00 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 0.7682, while it was recorded at 0.7084 for the last single week of trading, and 1.6165 for the last 200 days.

Evofem Biosciences Inc. [EVFM]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -23234.08 and a Gross Margin at -269.73. Evofem Biosciences Inc.’s Net Margin is presently recorded at -31907.85.

Return on Total Capital for EVFM is now -200.98, given the latest momentum, and Return on Invested Capital for the company is -590.20. Return on Equity for this stock declined to -1,675.90, with Return on Assets sitting at -205.85. When it comes to the capital structure of this company, Evofem Biosciences Inc. [EVFM] has a Total Debt to Total Equity ratio set at 6,380.10. Additionally, EVFM Total Debt to Total Capital is recorded at 98.46, with Total Debt to Total Assets ending up at 78.15. Long-Term Debt to Equity for the company is recorded at 2,319.30, with the Long-Term Debt to Total Capital now at 35.79.

Reflecting on the efficiency of the workforce at the company, Evofem Biosciences Inc. [EVFM] managed to generate an average of -$968,088 per employee. Receivables Turnover for the company is 0.45 with a Total Asset Turnover recorded at a value of 0.01.Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.

An analysis of insider ownership at Evofem Biosciences Inc. [EVFM]

There are presently around $26 million, or 29.80% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: VANGUARD GROUP INC with ownership of 7,009,858, which is approximately 68.313% of the company’s market cap and around 1.50% of the total institutional ownership; D. E. SHAW & CO., INC., holding 4,538,528 shares of the stock with an approximate value of $3.25 million in EVFM stocks shares; and MORGAN STANLEY, currently with $2.96 million in EVFM stock with ownership of nearly 3028.306% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 40 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 18,935,262 shares. Additionally, 60 investors decreased positions by around 25,213,351 shares, while 23 investors held positions by with 7,817,575 shares. The mentioned changes placed institutional holdings at 36,331,038 shares, according to the latest SEC report filing. EVFM stock had 20 new institutional investments in for a total of 2,774,205 shares, while 35 institutional investors sold positions of 18,488,083 shares during the same period.